PMID- 32961833
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240329
IS  - 2079-6382 (Print)
IS  - 2079-6382 (Electronic)
IS  - 2079-6382 (Linking)
VI  - 9
IP  - 9
DP  - 2020 Sep 18
TI  - Evaluation of Intravenous Fosfomycin Disodium Dosing Regimens in Critically Ill 
      Patients for Treatment of Carbapenem-Resistant Enterobacterales Infections Using 
      Monte Carlo Simulation.
LID - 10.3390/antibiotics9090615 [doi]
LID - 615
AB  - There are limited intravenous fosfomycin disodium (IVFOS) dosing regimens to 
      treat carbapenem-resistant Enterobacterales (CRE) infections. This study aimed to 
      use Monte Carlo simulation (MCS) for evaluation of IVFOS dosing regimens in 
      critically ill patients with CRE infections. The dosing regimens in critically 
      ill patients with various creatinine clearance were evaluated with MCS using 
      minimum inhibitory concentration (MIC) distributions of fosfomycin against CRE 
      clinical isolates in Thailand and the 24 h area under the plasma drug 
      concentration-time curve over the minimum inhibitory concentration 
      (AUC(0-24)/MIC) of >/=21.5 to be a target for IVFOS. The achieved goal of the 
      probability of target attainment (PTA) and a cumulative fraction of response 
      (CFR) were >/=90%. A total of 129 non-duplicated CRE clinical isolates had MIC 
      distributions from 0.38 to >1024 mg/L. IVFOS 8 g every 8 h, 1 h, or 4 h infusion, 
      could achieve approximately 90% PTA of AUC(0-24)/MIC target to treat CRE 
      infections with MICs </= 128 mg/L. According to PTA target, an IVFOS daily dose to 
      treat carbapenem-resistant Escherichia coli based on Clinical Laboratory 
      Standards Institute (CLSI) breakpoints for urinary tract infections and one to 
      treatment for CRE infections based on the European Committee on Antimicrobial 
      Susceptibility Testing (EUCAST) breakpoints were 16 g/day and 8 g/day, 
      respectively. All dosing regimens of IVFOS against CRE achieved CFR </= 70%. This 
      study proposes the IVFOS dosing regimens based on CLSI and EUCAST breakpoints for 
      the treatment of CRE infections. However, further clinical studies are needed to 
      confirm the results of these findings.
FAU - Leelawattanachai, Pannee
AU  - Leelawattanachai P
AD  - Division of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmacy, 
      Mahidol University, Bangkok 10400, Thailand.
AD  - Department of Pharmacy, Faculty of Medicine Vajira Hospital, Navamindradhiraj 
      University, Bangkok 10300, Thailand.
FAU - Wattanavijitkul, Thitima
AU  - Wattanavijitkul T
AD  - Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, 
      Chulalongkorn University, Pathumwan, Bangkok 10330, Thailand.
FAU - Paiboonvong, Taniya
AU  - Paiboonvong T
AD  - Department of Pharmacy Practice, College of Pharmacy, Rangsit University, Pathum 
      Thani 12000, Thailand.
FAU - Plongla, Rongpong
AU  - Plongla R
AUID- ORCID: 0000-0002-1622-1209
AD  - Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, 
      Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Thai Red 
      Cross Society, Bangkok 10330, Thailand.
AD  - Antimicrobial Resistance and Stewardship Research Unit, Chulalongkorn University, 
      Bangkok 10330, Thailand.
FAU - Chatsuwan, Tanittha
AU  - Chatsuwan T
AD  - Antimicrobial Resistance and Stewardship Research Unit, Chulalongkorn University, 
      Bangkok 10330, Thailand.
AD  - Department of Microbiology, Faculty of Medicine, Chulalongkorn University, 
      Bangkok 10330, Thailand.
FAU - Usayaporn, Sang
AU  - Usayaporn S
AD  - Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, 
      Chulalongkorn University, Pathumwan, Bangkok 10330, Thailand.
FAU - Nosoongnoen, Wichit
AU  - Nosoongnoen W
AD  - Division of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmacy, 
      Mahidol University, Bangkok 10400, Thailand.
FAU - Montakantikul, Preecha
AU  - Montakantikul P
AD  - Division of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmacy, 
      Mahidol University, Bangkok 10400, Thailand.
LA  - eng
PT  - Journal Article
DEP - 20200918
PL  - Switzerland
TA  - Antibiotics (Basel)
JT  - Antibiotics (Basel, Switzerland)
JID - 101637404
PMC - PMC7558518
OTO - NOTNLM
OT  - carbapenem-resistant Enterobacterales
OT  - critically ill patients
OT  - dosing regimens
OT  - intravenous fosfomycin disodium
OT  - pharmacokinetics/pharmacodynamics
COIS- The authors declare that they have no conflicts of interest in this research.
EDAT- 2020/09/24 06:00
MHDA- 2020/09/24 06:01
PMCR- 2020/09/18
CRDT- 2020/09/23 01:02
PHST- 2020/08/08 00:00 [received]
PHST- 2020/09/08 00:00 [revised]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2020/09/23 01:02 [entrez]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/09/24 06:01 [medline]
PHST- 2020/09/18 00:00 [pmc-release]
AID - antibiotics9090615 [pii]
AID - antibiotics-09-00615 [pii]
AID - 10.3390/antibiotics9090615 [doi]
PST - epublish
SO  - Antibiotics (Basel). 2020 Sep 18;9(9):615. doi: 10.3390/antibiotics9090615.